Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?

Individualising biologic disease-modifying anti-rheumatic drugs (bDMARDs) to maximise outcomes and deliver safe and cost-effective care is a key goal in the management of rheumatoid arthritis (RA). Investigation to identify predictive tools of bDMARD response is a highly active and prolific area of...

Descripción completa

Detalles Bibliográficos
Autores principales: Romão, Vasco C., Vital, Edward M., Fonseca, João Eurico, Buch, Maya H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655983/
https://www.ncbi.nlm.nih.gov/pubmed/29065909
http://dx.doi.org/10.1186/s13075-017-1445-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5655983/
https://www.ncbi.nlm.nih.gov/pubmed/29065909
http://dx.doi.org/10.1186/s13075-017-1445-3

Ejemplares similares